Oncolys BioPharma, Inc. (JP:4588) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oncolys BioPharma Inc. has completed enrollment for a Phase I clinical trial evaluating the safety and efficacy of their immunotherapy drug, Telomelysin (OBP-301), in advanced esophageal or gastro-esophageal cancer patients ineligible for surgery. This trial involves a combination of Telomelysin with chemoradiation and follows successful preliminary results in Japan, where Oncolys plans to submit a New Drug Application by end of 2024. The study’s completion marks a significant step towards potential new treatment options for these cancer patients.
For further insights into JP:4588 stock, check out TipRanks’ Stock Analysis page.